Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Luneau

Internal Medicine Pinehurst, NC Medical Doctor

NPI 1972665529 CMS profile 761203

15 Regional Dr, Pinehurst, NC 28374

Open in the dashboard

General payments

$3,374

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Luneau of Pinehurst, NC is reported in the CMS Open Payments database as having received $3,374 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $605 34
2024 General $942 43
2023 General $784 41
2022 General $371 23
2021 General $386 14
2020 General $15 1
2019 General $271 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Luneau
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Scott Luneau were reported at $605. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Scott Luneau Internal Medicine median Middle half National median
2019 $271 $159 $48–$570 $163
2020 $15 $119 $33–$402 $114
2021 $386 $135 $37–$521 $132
2022 $371 $141 $42–$496 $149
2023 $784 $149 $45–$519 $160
2024 $942 $154 $47–$537 $164
2025 $605 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $433 21 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $340 19 payments
  3. Lilly USA, LLC $300 12 payments
  4. Janssen Pharmaceuticals, Inc $269 11 payments
  5. GlaxoSmithKline, LLC. $214 8 payments
  6. Amgen Inc. $194 14 payments
  7. Pfizer Inc. $143 9 payments
  8. Esperion Therapeutics, Inc. $125 1 payment
  9. Grifols USA, LLC $98 5 payments
  10. Exact Sciences Corporation $86 5 payments
  11. Other $1,172 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,360 171 payments
  2. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. INJECTAFER $433 21 payments
  2. XARELTO $269 11 payments
  3. ZEPBOUND $238 9 payments
  4. SHINGRIX $214 8 payments
  5. NEXLETOL $125 1 payment
  6. NEXLIZET $125 1 payment
  7. JARDIANCE $119 7 payments
  8. Otezla $99 7 payments
  9. Prolastin-C Liquid $98 5 payments
  10. EVENITY $95 7 payments
  11. Other $2,302 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 192 drugs

Part D claims

17,256

Median for Internal Medicine: 777

Drug cost

$1,192,503

Median for Internal Medicine: $73,373

Branded share of claims

14.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 223 $229,939
Ozempic Semaglutide Brand 144 $163,950
Jardiance Empagliflozin Brand 132 $137,995
Mounjaro Tirzepatide Brand 64 $75,179
Januvia Sitagliptin Phosphate Brand 51 $67,588
Xarelto Rivaroxaban Brand 52 $61,060
Trulicity Dulaglutide Brand 41 $47,644
Linzess Linaclotide Brand 38 $36,639
Myrbetriq Mirabegron Brand 44 $24,448
Farxiga Dapagliflozin Propanediol Brand 22 $23,102

The 10 drugs with the highest cost, of 192 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 159 billing codes

Paid by Medicare

$388,122

Of which drugs: $135,475

Medicare patients

1,010

Average age 75

Services billed

44,363

504 women, 506 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Chronic kidney disease 32%
Diabetes 26%
Ischemic heart disease 26%
Osteoporosis 24%
Depression 22%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 65 4,800 $99,137
Injection, ferric carboxymaltose, 1 mg J1439 Office 28 26,250 $22,641
Vaccine for influenza for injection into muscle 90653 Office 121 121 $9,900
Injection, zoledronic acid, 1 mg J3489 Office 52 260 $1,042
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 89 206 $174
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 1,250 $131

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $198
$198 — —
INJECTAFER
  • Daiichi Sankyo Inc. $157
$157 — 26,250
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $53
  • Lilly USA, LLC $28
$81 132 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $49
$49 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record